MedeliX
Start asking

Bromfenac

Yellox · ATC code S01BC11

Also known as: Bromfenak

Key facts
Active substance
Bromfenac
ATC code
S01BC11
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Yellox 0.9 mg/ml eye drops solution
Marketing authorisation holder
Bausch + Lomb Ireland Limited
Information as of
2026-10-28

Key facts

Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) for use in the eye. It is used in adults to treat inflammation after cataract surgery.

What it is used for

  • Treatment of postoperative ocular inflammation following cataract extraction in adults.

Dosing

  • Yellox (eye drops): one drop in the affected eye(s) twice daily, beginning the day after cataract surgery and continuing through the first 2 weeks of the postoperative period.
  • Treatment should not exceed 2 weeks, as safety data beyond this are not available.
  • Applies to adults including the elderly; not studied in hepatic disease or renal impairment.
  • If more than one eye medicine is used, administer each at least 5 minutes apart.

Contraindications

  • Hypersensitivity to bromfenac, to any of the excipients, or to other NSAIDs.
  • Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or other prostaglandin synthetase inhibitors.

Important warnings

  • Topical NSAIDs may slow or delay healing; concomitant topical steroids may increase the potential for healing problems.
  • In susceptible patients, epithelial breakdown, corneal thinning, erosion, ulceration or perforation can occur and may be sight threatening; discontinue immediately if epithelial breakdown occurs.
  • Higher risk of corneal reactions with complicated or repeat ocular surgery, diabetes mellitus, dry eye syndrome or rheumatoid arthritis, among others.
  • Possible increased bleeding of ocular tissues; caution with bleeding tendencies or medicines that prolong bleeding time.
  • May mask an acute ocular infection. Contains benzalkonium chloride; contact lenses should not be worn during treatment.

Side effects

  • Overall, 3.4% of patients experienced one or more adverse reactions.
  • Most common or important: abnormal sensation in eye (0.5%), mild or moderate corneal erosion (0.4%), eye pruritus (0.4%), eye pain (0.3%) and eye redness (0.3%).
  • Uncommon: visual acuity reduced, corneal oedema, vision blurred, eyelid bleeding, haemorrhagic retinopathy.

Interactions

  • No interaction studies have been performed; no interactions with antibiotic eye drops used in conjunction with surgery have been reported.

Pregnancy and breastfeeding

  • During the first and second trimester use only if clearly necessary; not recommended during the last trimester.
  • Can be used during breast-feeding.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • YelloxBausch + Lomb Ireland Limited · EMEA/H/C/001198

Source: European Medicines Agency (EMA), product information

Turkey

  • ProlensaBAUSCH & LOMB SAĞLIK VE OPTİK ÜRÜNLERİ TİC. A.Ş. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 13 more European countries
Cyprus
Eyebrom
Czechia
Bromfenac Olikla
Finland
Bromfenac
Greece
Eyebrom
Iceland
Yellox
Italy
Bromoftil, Coxafen, Iolac, Irgass, Sinnalca
Liechtenstein
Yellox
Netherlands
Bromfenac, Broomfenac Ntc, Broomfenac Rafarm
Norway
Bromfenac Blumont, Yellox
Poland
Brofestill, Broftyal, Bromfenacum Brofestill Krople Do Oczu Roztwór W Pojemniku Jednodawkowym, Infladrop
Portugal
Brovit, Katlox
Slovakia
Bromfenac Olikla
Spain
Alcarix, Eyebrom, Redenac

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Yellox – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/yellox-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.